Results 251 to 260 of about 30,760,761 (278)

Super-Enhancer-Driven IRF2BP2 is Activated by Master Transcription Factors and Sustains T-ALL Cell Growth and Survival. [PDF]

Adv Sci (Weinh)
Yu J, Zhang Z, Chen Y, Wang J, Li G, Tao Y, Zhang Y, Yang Y, Zhang C, Li T, Cheng J, Ji T, Wei Z, Wang W, Fang F, Jiang W, Chu P, Yin H, Wu D, Li X, Wang X, Fan JJ, Hu S, Zhu ZH, Wu S, Lu J, Pan J.   +26 more
europepmc   +1 more source

Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL). [PDF]

Exp Mol Med
Lyu A, Nam SH, Humphrey RS, Horton TM, Ehrlich LIR.   +4 more
europepmc   +1 more source

Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk. [PDF]

Cancer Discov
Kimura S, Park CS, Montefiori LE, Iacobucci I, Pölönen P, Gao Q, Arnold ED, Attarbaschi A, Brown A, Buldini B, Caldwell KJ, Chang Y, Chen C, Cheng C, Cheng Z, Choi J, Conter V, Crews KR, de Groot-Kruseman HA, Deguchi T, Eguchi M, Muhle HE, Elitzur S, Escherich G, Freeman BB, Gu Z, Han K, Horibe K, Imamura T, Jeha S, Kato M, Chiew KH, Khan T, Kicinski M, Köhrer S, Kornblau SM, Kotecha RS, Li CK, Liu YC, Locatelli F, Luger SM, Paietta EM, Manabe A, Marquart HV, Masetti R, Maybury M, Mazilier P, Meijerink JPP, Mitchell S, Miyamura T, Moore AS, Oshima K, Pawinska-Wasikowska K, Pieters R, Prater MS, Pruett-Miller SM, Pui CH, Qu C, Reiterova M, Reyes N, Roberts KG, Rowe JM, Sato A, Schmiegelow K, Schrappe M, Shen S, Skoczeń S, Spinelli O, Stary J, Svaton M, Takagi M, Takita J, Tang Y, Teachey DT, Thomas PG, Tomizawa D, Trka J, Varotto E, Vincent TL, Yang JJ, Yeoh AEJ, Zhou Y, Zimmermann M, Inaba H, Mullighan CG.   +84 more
europepmc   +1 more source

TdT Negative T-ALL.

The Western journal of medicine, 2010
S, Lee, D, Rosenbaum
openaire   +1 more source

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.

Blood
Han Q, Gu Y, Xiang H, Zhang L, Wang Y, Yang C, Li J, Steiner C, Lapalombella R, Woyach JA, Yang Y, Dovat S, Song C, Ge Z.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The T-ALL paradox in cancer

Nature Medicine, 2010
Overexpression of T cell leukemia homeobox 1 (TLX1) occurs in some leukemias. New findings in mice and humans show how TLX1 drives chromosomal aberrations and deletions of tumor suppressor genes during T-cell transformation (pages 1321–1327). Surprisingly, its expression does not correlate with bad prognosis.
Hoang, Trang, Hoang, Thu
openaire   +1 more source

Human T-ALL Xenografts

2020
Intense chemotherapy regimens of patients diagnosed with T cell acute lymphoblastic leukemia (T-ALL) have proved successful for improving patient's overall survival, especially in children. But still T-ALL treatment remains challenging, since side effects of chemotherapeutic drugs often worsen patient's quality of life, and relapse rates remain ...
Patricia, Fuentes, María L, Toribio, Sara, González-García   +2 more
openaire   +2 more sources

Late Relapses of Childhood T-ALL Are Frequently Second T-ALL.

Blood, 2007
Abstract The vast majority of relapses in childhood T-cell acute lymphoblastic leukemia (T-ALL) patients occur relatively early, usually within 2 years from diagnosis. Our previous comparative molecular analyses between diagnosis and relapse in all such “classical” T-ALL showed totally or at least partly identical T-cell receptor (TCR ...
Jacques J.M. van Dongen, Jules P.P. Meijerink, Elisabeth van Wering, Andre Schrauder, Dario Campana, Udo zur Stadt, Helene Cave, Monica Spinelli, Renate Panzer-Grumayer, Bernd Gruhn, Pieter Van Vlierberghe, Vincent H.J. van der Velden, Tomasz Szczepanski   +12 more
openaire   +1 more source

Notch, a T-ALL order

Blood, 2011
In this issue of Blood , Demarest et al demonstrate that maintenance of T-cell acute lymphoblastic leukemia (T-ALL) tumors requires continued expression of activated Notch1 while c-Myc expression is expendable for tumor maintenance.[1][1] The data reported in this paper use a mouse model ...
openaire   +2 more sources

ZEB2 in T-cells and T-ALL

Advances in Biological Regulation, 2019
The identification of the rare but recurrent t(2; 14)(q22; q32) translocation involving the ZEB2 locus in T-cell acute lymphoblastic leukemia, suggested that ZEB2 is an oncogenic driver of this high-risk subtype of leukemia. ZEB2, a zinc finger E-box homeobox binding transcription factor, is a master regulator of cellular plasticity and its expression ...
Stien, De Coninck, Geert, Berx, Tom, Taghon, Pieter, Van Vlierberghe, Steven, Goossens   +4 more
openaire   +2 more sources